伊立替康联合顺铂治疗进展期食管鳞癌的疗效观察  

Irinotecan Combined with Cisplatin in Advanced Esophageal Squamous Cell Carcinoma

作　　者：宋敏[1] 李磊[1] 常志伟[1] 薄志广 常志军 杨广义[3] 王静[3] 畅捷[1] 

机构地区：[1]郑州大学第一附属医院肿瘤科,河南省郑州市450052 [2]林州市中心医院胸外科 [3]安阳市肿瘤医院肿瘤科

出　　处：《中国全科医学》2013年第14期1669-1671,共3页Chinese General Practice

摘　　要：目的观察伊立替康联合顺铂治疗进展期食管鳞癌的疗效。方法 2007-05-20—2009-05-20共入组进展期食管鳞癌患者46例,采用伊立替康75 mg/m2,持续静脉滴注90 min,第1、8天;顺铂25 mg/m2,静脉滴注,第1～3天;21 d为1个周期;至少完成2个周期化疗者方可评价疗效。结果本组46例患者共完成188个化疗周期,在可评价疗效的45例患者中,完全缓解5例,部分缓解16例,稳定13例,进展11例,有效率为46.7%(21/45),疾病控制率为75.6%(34/45);1年生存率为20.0%(9/45),中位疾病进展时间为5.0个月〔95%CI(3.9,6.1)〕,中位生存时间为9.0个月〔95%CI(8.3,9.7)〕;化疗主要毒副作用为腹泻、脱发、恶心、血小板减少、粒细胞减少、呕吐等。结论伊立替康联合顺铂治疗进展期食管鳞癌疗效确切,安全性及患者依从性好,可作为进展期食管鳞癌的治疗方案。Objective To investigate the efficacy and toxicity of irinotecan combined with cisplatin in treatment for pa- tients with advanced esophageal squamous cell carcinoma. Methods A total of 46 patients with advanced esophageal squmous cell carcinoma admitted from May 2007 to May 2009 were given irinotecan, 75 mg/m2 , iv gtt for 90 rain, on days 1, 8, and cisplatin 25 mgc/m2, iv gtt, on day 1 ~ 3. One cycle lasted 21 d. The effect was evaluated at least after 2 cycles. Results This group of patients completed altogether 188 cycles. In 45 patients whose effects were evaluable, 5 remitted completely, 16 partly, 13 had stable condition, 11 had progression, the effective rate was 46. 7% （21/45）, disease control rate was 75.6% （34/45） , 1 -year survival rate was 20. 0% （9/45） , median progressive time was 5.0 months [95%CI （3.9, 6. 1 ） ] , me- dian survival time was 9. 0 months [95% CI （8.3, 9. 7） 1. The main toxicity of chemotherapy were diarrhea, hair loss, nause- a, thromboeytopenia, neutropenia, vomiting. Conclusion The effectiveness of irinotecan combined with cisplatin treating ad- vanced esophageal squmous cell carcinoma is definite with good safety and patients＇compliance, which can be used as treatment programs for advanced esophageal squamous cell carcinoma.

关 键 词：伊立替康 顺铂 食管肿瘤 抗肿瘤联合化疗方案 

分 类 号：R735.1[医药卫生—肿瘤]